Themis Medicare Limited · NSE:THEMISMED
Themis Medicare — Q2 FY25 Earnings Presentation
19 slides from Themis Medicare's earnings presentation, Oct 25, 2024
Slide 1: Exchange covering letter for Investor Presentation
‘ TML: CS: BSE/NSE CORR: 2024-25 25th October, 2024 Listing Department, Listing Department, BSE Limited, National Stock Exchange of India Ltd. P. J. Towers, Dalal Street, “Exchange Plaza”, Mumbai-400001 Bandra – Kurla Complex, BSE Scrip Code: 530199 Bandra – East, Mumbai- 400 051 NSE Scrip Code: THE
Slide 2: Themis Medicare Ltd. Result Update Presentation Q2 & H1 FY25
In every possibility lies an innate, latent power to change lives Themis Medicare Ltd. Result Update Presentation Q2 & H1 FY25
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Themis Medicare Limited (the “Company” or “Themis” or “TML”) solely for information purposes and does not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in
Slide 4: Table of Contents
Table of Contents Consolidated Financial Highlights Company Overview Way Ahead 3
Slide 5: Consolidated Financial Highlights
Consolidated Financial Highlights
Slide 6: Management Comment
Management Comment Commenting on the result, Dr. Sachin Patel, Managing Director & CEO, said: “I am happy to report that we have closed the second quarter of this fiscal on a strong note with performance in line with strategic objectives. Our plans, developed and implemented over the past few quarte
Slide 7: Consolidated Quarterly Financial Highlights
Consolidated Quarterly Financial Highlights Revenue (Rs. Cr.)* EBITDA (Rs. Cr.)** / Margin (%) 123.0 30 23.7% 117.0 25% 104.8 97.8 25 29.2 20% 82.5 20 14.6% 11.8% 15% 15 9.8% 9.5% 17.1 10% 10 12.4 5 9.3 5% 8.1 0 0% Q2 FY24 Q3 FY24 Q4 FY24 Q1 FY25 Q2 FY25 Q2FY24 Q3FY24 Q4FY24 Q1 FY25 Q2 FY25 PAT (Rs.
Slide 8: Consolidated Quarterly Financial Highlights – Q2 FY25
Consolidated Quarterly Financial Highlights – Q2 FY25 Particulars (Rs. Cr.) Q2 FY25 Q2 FY24 Y-o-Y (%) Q1 FY25 Net Revenue 117.01 104.78 11.67% 122.99 Cost of Material Consumed 21.06 26.18 23.52 • Formulation Segment has grown by Purchase of SIT 18.12 13.92 16.74 >36% year-on-year for Q2 FY25 Changes
Slide 9: Consolidated Half-Yearly Financial Highlights – H1 FY25
Consolidated Half-Yearly Financial Highlights – H1 FY25 Particulars (Rs. Cr.) H1 FY25 H1 FY24 Y-o-Y (%) Net Revenue 240.00 201.43 19.15% Cost of Material Consumed 44.58 41.89 Purchase of SIT 34.86 23.71 Changes in Inventory 3.47 5.41 Employee Expenses 45.97 40.03 Other Expenses 64.82 56.25 Total Exp
Slide 10: Consolidated Balance Sheet as on 30th Sep'24
Consolidated Balance Sheet as on 30th Sep’24 As on 30th As on 31st As on 30th As on 31st Rs. Cr. Rs. Cr. Sep’24 Mar’24 Sep’24 Mar’24 Shareholders Funds 412.01 377.67 Non Current Assets 290.12 273.25 Share Capital 9.20 9.20 Plant, Property & Equipment 173.33 167.81 Other Equity 402.81 368.46 Capital
Slide 11: Company Overview
Company Overview
Slide 12: Snapshot of Company
Snapshot of Company Strategic focus To become Leader in Hospital Business in India with 4 Strong Balance Sheet growing divisions contributing 36% to revenue in FY23-24 Total Debt to Equity at 0.25 in FY23-24 3 State of art manufacturing facilities in India – Rs. 2,515 Cr 1 Formulations and 2 APIs (S
Slide 13: Strong Business Model
Strong Business Model 01 Businesswise Revenue – H1 FY24-25 Hospital Business Hospital API, Co. is major growth 03 Mkt & 36% driver Others 45% Trade 19% n 02 n Hospital Business API Business Critical Care Division API Legacy Business Intensive Care Division New Product pipeline Businesswise R
Slide 14: Vertically Integrated State of Art Manufacturing Capabilities
Vertically Integrated State of Art Manufacturing Capabilities Location Particulars Haridwar Hyderabad Vapi Artemis Biotech Themis Medicare Ltd. Themis Medicare Ltd. (Division of Themis Medicare Ltd.) Segment Formulations Synthetic APIs Synthetic APIs Tablets (Nos.) - 520 mn Ointment (No. of Tubes) -
Slide 15: Strong Research and Development Capabilities
Strong Research and Development Capabilities Continued Investment in R&D (Rs. Cr.) Business API Formulations 14.25 13.64 13.69 R&D 11 7 Analytical Lab 8.50 8 8 Development 4.59 Product in a year with 3.43 5–8 20-24 documentation FY18-19 FY19-20 FY20-21 FY21-22 FY22-23 FY23-24 Products in work rollin
Slide 16: Way Ahead
Way Ahead
Slide 17: Hospital Business Opportunity
n Hospital Business Opportunity Why Hospital Business Segment? Growing market - Themis has strong foot in door through Critical Care Market Highly Fragmented unlike West where 3-4 players control 90% market share Opportunities to grow segments within HB High Entry Barriers Large Product Port
Slide 18: Our Aspirations
Our Aspirations Vision & Position Provide hospitals and health systems ‘The Best Experience Leader business model” to ensure customer satisfaction Leadership in Anesthesia and Critical Care Strategy Focus on Hospital business APIs to be developed - in-house New Target Markets consumption and
Slide 19: Thank You
Thank You It takes one word to change the world “POSSIBILITY” For further information, please contact: Mr. Sangameshwar Iyer Mr. Amit Sharma / Ms. Disha Shah Tel: +91 9867726686 / 9699060134 Themis Medicare Ltd Adfactors PR Pvt Ltd Email: sangameshwar.iyer@themismedicare.com Email: amit.sharma@adfac